Emerging retatrutide, a twin -action treatment targeting both GLP-1 and GIP receptors, is creating considerable buzz within the weight loss community. Early clinical trials have shown significant losses in physical size and improvements in physiological markers for patients with obesity . Researchers believe this unique approach has the potential t